ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AKBA Akebia Therapeutics Inc

2.75
0.51 (22.77%)
Pre Market
Last Updated: 04:30:48
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,310,994
Bid Price 2.75
Ask Price 2.76
News (1)
Day High

Low
0.4901

52 Week Range

High
2.335

Day Low
Company Name Stock Ticker Symbol Market Type
Akebia Therapeutics Inc AKBA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.51 22.77% 2.75 04:30:48
Open Price Low Price High Price Close Price Prev Close
2.24
Trades Volume Avg Volume 52 Week Range
6,845 1,310,994 - 0.4901 - 2.335
Last Trade Time Type Quantity Stock Price Currency
04:30:48 formt 600 $ 2.75 USD

Akebia Therapeutics (AKBA) Options Flow Summary

Overall Flow

Bullish

Net Premium

71k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Akebia Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
468.99M 209.37M - 292.6M -92.56M -0.44 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Akebia Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No AKBA Message Board. Create One! See More Posts on AKBA Message Board See More Message Board Posts

Historical AKBA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.962.3351.912.138,568,3690.7940.31%
1 Month1.582.3351.341.855,302,0801.1774.05%
3 Months1.382.3351.291.713,260,9431.3799.28%
6 Months1.182.3350.78011.492,267,3251.57133.05%
1 Year0.64012.3350.49011.351,997,4392.11329.62%
3 Years3.104.330.2411.353,673,001-0.35-11.29%
5 Years8.4613.780.2412.483,394,014-5.71-67.49%

Akebia Therapeutics Description

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.

Your Recent History

Delayed Upgrade Clock